GRACE
A

CAR T-Cell vs. Bispecific Therapies for Blood Cancers: How Oncologists Determine Treatment

By GRACE FEATURING Aaron Goodman, Autumn Jeong, Sridevi Rajeeve
By GRACE FEATURING Aaron Goodman, Autumn Jeong, Sridevi Rajeeve
2,008 views
June 30, 2023
Comments 0
Login to view comments. Click here to Login

Featured Video

15:43
Incyte

Importance of Early Management of Patients with Myelofibrosis (MF)

Feat. P. Bose, R. Rampal

Featured Video

16:51
Incyte

Effects of PV Treatment on White Blood Cell Count and Thrombotic Risk

Feat. C. Harrison

Recommended

17:52

2024 Updates on Emerging & Current Treatment of Multiple Myeloma

Indy Hematology Review

K. Anderson

1.2K views

·

7 months ago
16:42

ASH 2023 Summary: "The Best of Myeloma - Highlights & Key Takeaways"

Insights from 2023 ASH Annual Meeting

H. Hashmi

1.6K views

·

10 months ago
24:35

ASCO® 2024 Summary: "The Best of Myeloma - Review of the Top 5 Abstr…

2024 ASCO® Annual Meeting Insights Hub

H. Hashmi

616 views

·

4 months ago
35:27

Advances in Multiple Myeloma 2024: From Bench to Bedside

Dana-Farber Cancer Institute

K. Anderson

631 views

·

4 months ago
26:59

Multiple Myeloma: A Journey From Pharaoh's Times to 2024

Houston Methodist

S. Ganguly

135 views

·

2 months ago
15:35

Multiple Myeloma: Not as Simple as "CRAB" Anymore

Fred Hutch 14th Annual Comprehensive Hematology & Oncology Review Course

R. Banerjee

368 views

·

3 months ago
24:23

Will CAR-Ts and Bispecifics Replace HSCT in Myeloma?

MyCancerHaven

R. Vij, S. Al Hadidi

619 views

·

5 months ago
20:23

When to Consider Bispecific and CAR-T Therapy in MM

SOHO Brazil 2024

N. S. Raje

401 views

·

4 months ago
19:08

ASH 2023 Summary: "Practice Changing Updates in MM, SMM and MGUS Fro…

Insights from 2023 ASH Annual Meeting

R. Banerjee

870 views

·

9 months ago
36:10

Highlights in Plasma Cell Disorders From ASCO® and EHA

Insights from 2024 EHA Annual Meeting

S. Al Hadidi

466 views

·

4 months ago
14:01

ESMO 2024 Summary: Highlights in Heme Malignancies

2024 ESMO Annual Meeting Insights Hub

M. Gomes da Silva

414 views

·

1 month ago
45:56

Endocrine Adverse Events From Checkpoint Inhibitors

Yale Cancer Center

K. Herold

867 views

·

9 months ago
09:07

CARTITUDE-4 Update: OS With Cilta-Cel vs. SOC in Len-Refractory Mult…

Maria-Victoria Mateos

205 views

·

1 month ago
26:46

CAR-Ts Earlier in MyelomaTherapy?: What We Learned From the Recent F…

Samer Al Hadidi

599 views

·

7 months ago
05:35

Bispecifics & CAR-Ts in MM: How to Choose and How to Sequence

Saurabh Chhabra

382 views

·

7 months ago
20:18

Will Immune Therapy Replace Transplant in Hematologic Malignancies?

XIV Eurasian Hematology-Oncology Congress - EHOC 2023

R. Gale

505 views

·

8 months ago
45:27

Cellular Therapy in 2024: What, Why, When, Who… and Where Are We Goi…

University of Colorado Department of Medicine

J. Gutman

263 views

·

2 months ago
20:19

ASCO® 2023 Insights: "Highlights of Hematologic Malignancies - Multi…

Insights from 2023 ASCO® Annual Meeting

A. Paulus

1.8K views

·

1 year ago
03:42

Multiple Myeloma: What You Need to Know About New FDA Approvals of C…

Moffitt Cancer Center

D. Hansen

375 views

·

7 months ago
17:22

Highlights of Recent Updates in Myeloma: Part 2 - R/R Treatment

2024 ASCO® Annual Meeting Insights Hub

A. Jakubowiak

249 views

·

3 months ago
AUTOPLAY